Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

XEN901 · NBI-921352

Small molecule · developed by Neurocrine Biosciences

Phase 1 Most advanced trial (none active)
1 Registered trials

What is XEN901?

XEN901 is an investigational small-molecule drug studied in Healthy Volunteers.

At a glance

Also known as
NBI-921352
Drug type
Small molecule
Developer
Neurocrine Biosciences
In trials of
XENE
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
SV2WPA4R4J

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03467100 Phase 1 Healthy Volunteers Completed XENE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.